Literature DB >> 8876027

Persisting changes in brain glucose uptake following neurotoxic doses of phencyclidine which mirror the acute effects of the drug.

G D Ellison1, A S Keys.   

Abstract

Phencyclidine (PCP) can induce a model psychosis which has a number of similarities to dementias and schizophrenia. In some cases the psychosis persists for prolonged periods after drug discontinuation. N-Methyl-D-aspartate (NMDA) antagonists such as PCP induce increases in glucose metabolism in a variety of brain structures but most notably in limbic regions such as retrosplenial, piriform, and entorhinal cortex, hippocampus, and olfactory tubercle. When given continuously for several days, these NMDA antagonists induced neural degeneration in these same critical limbic areas. In the present study regional 2-fluorodeoxyglucose (FDG) uptake was measured in rats at both 24 h and 10 days after neurotoxic, 5-day "binge" PCP administration. At 24 h after minipump removal there were persisting and large increases in glucose uptake in many brain regions, with maximal changes in the same limbic structures in which neurotoxicity has been observed. Surprisingly, many of these regions still showed elevated glucose metabolism after 10 days of recovery. These findings suggest an anatomical and neurochemical substrate for the persisting psychosis which can occur following PCP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8876027     DOI: 10.1007/bf02246457

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Competitive and non-competitive NMDA antagonists induce similar limbic degeneration.

Authors:  G Ellison
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

2.  Effects of phencyclidine and stress on plasma creatine phosphokinase (CPK) and aldolase activities in man.

Authors:  H Y Meltzer; P S Holzman; S Z Hassan; A Guschwan
Journal:  Psychopharmacologia       Date:  1972

Review 3.  Phencyclidine (PCP): a review and perspectives.

Authors:  O Aniline; F N Pitts
Journal:  Crit Rev Toxicol       Date:  1982-04       Impact factor: 5.635

4.  The effects of N-methyl-D-aspartate receptor blockade with MK-801 upon the relationship between cerebral blood flow and glucose utilisation.

Authors:  D G Nehls; C K Park; A G MacCormack; J McCulloch
Journal:  Brain Res       Date:  1990-03-19       Impact factor: 3.252

5.  Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.

Authors:  C A Tamminga; G K Thaker; R Buchanan; B Kirkpatrick; L D Alphs; T N Chase; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1992-07

6.  The regional distribution of d-amphetamine and local glucose utilization in rat brain during continuous amphetamine administration.

Authors:  M S Eison; A S Eison; G Ellison
Journal:  Exp Brain Res       Date:  1981       Impact factor: 1.972

7.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

8.  Development of dispositional tolerance to phencyclidine by osmotic minipump in the mouse.

Authors:  T Nabeshima; S P Sivam; C Y Tai; I K Ho
Journal:  J Pharmacol Methods       Date:  1982-05

9.  PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent.

Authors:  C A Tamminga; K Tanimoto; S Kuo; T N Chase; P C Contreras; K C Rice; A E Jackson; T L O'Donohue
Journal:  Synapse       Date:  1987       Impact factor: 2.562

Review 10.  The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias.

Authors:  G Ellison
Journal:  Brain Res Brain Res Rev       Date:  1995-02
View more
  2 in total

1.  The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications.

Authors:  N C Carty; J Xu; P Kurup; J Brouillette; S M Goebel-Goody; D R Austin; P Yuan; G Chen; P R Correa; V Haroutunian; C Pittenger; P J Lombroso
Journal:  Transl Psychiatry       Date:  2012-07-10       Impact factor: 6.222

2.  Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism.

Authors:  Just Genius; Johanna Geiger; Anna-Lena Dölzer; Jens Benninghoff; Ina Giegling; Annette M Hartmann; Hans-Jürgen Möller; Dan Rujescu
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.